Amgen Inc. $AMGN Shares Purchased by Mitsubishi UFJ Trust & Banking Corp

Key Points

• Mitsubishi UFJ Trust & Banking Corp increased its stake in Amgen by 5.2% in Q4, buying 14,425 shares to hold 290,302 shares worth about $95.0 million (≈0.05% of the company).
• Amgen beat Q4 expectations with $5.29 EPS (vs. $4.76 est.) and $9.87B revenue (vs. $9.46B est.), set FY2026 EPS guidance of 21.600–23.000, and analysts forecast roughly 22.16 EPS for the year.
• The company declared a quarterly dividend of $2.52 per share (annualized $10.08) with an ex-dividend/record date of May 15 and a payment date of June 5, implying about a 3.0% yield.

Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 290,302 shares of the medical research company's stock after purchasing an additional 14,425 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.05% of Amgen worth $95,022,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AMGN. Board of the Pension Protection Fund acquired a new stake in Amgen in the fourth quarter valued at approximately $26,000. Olistico Wealth LLC acquired a new position in Amgen during the 4th quarter worth approximately $33,000. Holos Integrated Wealth LLC purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $37,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $34,000. Finally, Saranac Partners Ltd acquired a new stake in shares of Amgen in the 3rd quarter valued at $37,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $340.11 on Tuesday. The company's fifty day moving average price is $360.16 and its 200 day moving average price is $340.08. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $183.55 billion, a P/E ratio of 23.90, a P/E/G ratio of 3.60 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.16 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is currently 70.84%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AMGN. Freedom Capital cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a research note on Thursday, February 5th. TD Cowen reaffirmed a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Wells Fargo & Company upped their price objective on Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 19th. Finally, Leerink Partners reiterated a "market perform" rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $356.62.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.